Suven Pharmaceuticals (SUVEN PHARMA) Share Price

Sector: Pharmaceuticals | ISIN: INE03QK01018
₹ 713.90 (-1.41%) icon21 Jun, 2024, 12:00:00 AM
Open
₹ 724.10
Prev. Close
₹ 724.10
Turnover(lac)
₹ 0.01
Day's High
₹ 725.55
Day's Low
₹ 706.35
52 Wk High
₹ 768.00
52 Wk Low
₹ 477.65
Book Value
₹ 80.69
Face Value
₹ 1.00
Mkt. Cap (Cr.)
₹ 18,173.39
P/E
60.47
EPS
11.97
Div. Yield
0.00

Suven Pharmaceuticals Ltd KEY RATIOS

sector: Pharmaceuticals

  • CMP

    as on 6/21/2024 12:00:00 AM

    ₹ 713.9 -10.20 -1.41
  • Open
  • ₹ 724.1
  • Prev. Close
  • ₹ 724.1
  • Turnover(Lac.)
  • ₹ 1,143
  • Day's High
  • ₹ 725.55
  • Day's Low
  • ₹ 706.35
  • 52 Week's High
  • ₹ 768
  • 52 Week's Low
  • ₹ 477.65
  • Book Value
  • ₹ 80.69
  • Face Value
  • ₹ 1
  • Mkt Cap (₹ Cr.)
  • 18,173.39
  • P/E
  • 60.47
  • EPS
  • 11.97
  • Divi. Yield
  • 0

Suven Pharmaceuticals Ltd Corporate Actions

20 May , 2024

12:00 AM

20 May , 2024

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

29 Feb , 2024

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

29 Jan , 2024

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

29 Jan , 2024

12:00 AM

21 Dec , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

09 Nov , 2023

12:00 AM

AGM

Announcement date: 09 Nov , 2023

View Details

02 Nov , 2023

12:00 AM

02 Nov , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

29 Sep , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

01 Aug , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

01 Aug , 2023

12:00 AM

10 Nov , 2023

12:00 AM

BookCloser

View Details

No Record Found


Suven Pharmaceuticals Ltd News and Update

No Record Found

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required

Suven Pharmaceuticals Ltd SHAREHOLDING SNAPSHOT 21 June , 2024 | 06:34 PM

PROMOTER - TOTAL50.10%

Indian: 0.00%

Foreign: 50.101%

NON-PROMOTER - TOTAL 49.90%

Institutions: 26.80%

Non-Institutions: 23.10%

CUSTODIES - 0.00%

Custodies: 0.00%

See More Details
ad IconAd Image

Suven Pharmaceuticals Ltd FINANCIALS

View Profit & Loss Graph

Suven Pharmaceuticals Ltd PEER COMPARISON

Figures of Market Capital(Mar Cap), Quaterly Net Profit(NP Qtr) and Quaterly Sales(Sales Qtr) are in ₹ Cr.View All Peer Comparison

MORE ABOUT Suven Pharmaceuticals Ltd

  • Hanumantha Rao Kokkonda
  • Company Sec. & Compli. Officer
  • Shweta Jalan
  • Non Executive Director
  • U B Pravin Rao
  • Independent Director
  • Annaswamy Vaidheesh
  • Executive Chairman
  • Venkatanaga Kali Vara Prasad Raju Vetukuri
  • Managing Director
  • Pankaj Patwari
  • Non Executive Director
  • Matangi Gowrishankar
  • Independent Director
  • Vinod Rao
  • Independent Director
  • K G Ananthakrishnan
  • Independent Director

Summary

Suven Pharmaceuticals Limited (SPL) is a bio-pharmaceutical company, incorporated on 6th November, 2018 and is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies. The Company is a CDMO that supports global life sciences industry and fine chemical majors in their NCE development endeavors. Its services include custom synthesis, process R&D, scale-up and contract manufacturing of intermediates, APIs and formulations. Suven Pharma Inc., a Delaware Company, is a WOS (wholly owned subsidiary) of SPL, is a SPV (Special Purpose Vehicle) created on 9th March 2019, for undertaking various business opportunities in Pharma Industry.During the year 2019-20, Suven Life Sciences Ltd. (SLSL) has transferred the CRAMS business undertaking to the Company in accordance with the Scheme of Arrangement (Demerger) approved by the Honble NCLT, Hyderabad Bench now integrated with Contract Development and Manufacturing Operations (CDMO) business model of the Company. In terms of the sanctioned Scheme, the Company issued and allotted 1 (One) fully paid up equity share of face value of Re 1/- (Rupee One only) each of SPL for every 1 (One) fully paid up equity share of face value of Re 1/- (Rupee One only) each held by each shareholder in the Demerged... Read More


Reports by Suven Pharmaceuticals Ltd


Reports by Suven Pharmaceuticals Ltd

Company FAQ


No Record Found